DEA
BMY icon

DoubleLine ETF Adviser’s Bristol-Myers Squibb BMY Stock Holding History

DoubleLine ETF Adviser’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.58M Buy
+26,054
New +$1.52M 0.6% 46

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DoubleLine ETF Adviser's BMY Position: Q1 2026 in Review

DoubleLine ETF Adviser opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 26,054 shares worth $1.58M. The stake represents 0.6% of the portfolio and ranks #46 among its holdings.

2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • DoubleLine ETF Adviser held 26,054 shares of Bristol-Myers Squibb worth $1.58M as of Q1 2026.
  • Bristol-Myers Squibb was a new DoubleLine ETF Adviser position in Q1 2026.
  • Bristol-Myers Squibb made up 0.6% of DoubleLine ETF Adviser's portfolio in Q1 2026, its #46 holding.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q1 2026, filed 15 May 2026.